Polycystic ovary syndrome (PCOS) is the most common endocrine disorder that significantly affects both obese and non-obese women of reproductive age. Besides genetic and epigenetic factors, obesity and insulin resistance (IR) play a key role in the pathogenesis of PCOS, contributing to its endocrine, reproductive, and metabolic manifestations. Even though metformin remains a well-established treatment in the management of PCOS, emerging therapies and integrative approaches warrant comparison. This narrative review aims to understand the pathophysiology of PCOS and compare the role of metformin with that of new emerging therapies, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors, oral contraceptive pills (OCPs), inositol supplements, and lifestyle modifications, thereby empowering clinicians to provide personalized medicine based on each patient's unique presentation. This review explores the safety, efficacy, and clinical outcomes of these interventions on weight reduction, hormonal balance, menstrual regularity, and metabolic outcomes in both obese and non-obese women with PCOS.
Abstract
Journal Article
Review
eng
40842765
Telagarapu, Venkata Madhavi Latha, et al. "Revisiting Metformin in the Management of Polycystic Ovary Syndrome (PCOS)." Cureus, vol. 17, no. 7, 2025, pp. e88216.
Telagarapu VML, Nallamothu PD, Telagarapu VN, et al. Revisiting Metformin in the Management of Polycystic Ovary Syndrome (PCOS). Cureus. 2025;17(7):e88216.
Telagarapu, V. M. L., Nallamothu, P. D., Telagarapu, V. N., Nalluri, S. R. C., Nathani, S., Kopani, C. P., Yarraguntla, V., & Vyasalapu, S. (2025). Revisiting Metformin in the Management of Polycystic Ovary Syndrome (PCOS). Cureus, 17(7), e88216. https://doi.org/10.7759/cureus.88216
Telagarapu VML, et al. Revisiting Metformin in the Management of Polycystic Ovary Syndrome (PCOS). Cureus. 2025;17(7):e88216. PubMed PMID: 40842765.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Revisiting Metformin in the Management of Polycystic Ovary Syndrome (PCOS).
AU - Telagarapu,Venkata Madhavi Latha,
AU - Nallamothu,Priyanka Devi,
AU - Telagarapu,Venkata Nikhila,
AU - Nalluri,Srikar Raja Chowdary,
AU - Nathani,Saispoorthy,
AU - Kopani,Chandu Priya,
AU - Yarraguntla,Vishnu,
AU - Vyasalapu,Sriharika,
Y1 - 2025/07/18/
PY - 2025/07/18/accepted
PY - 2025/8/22/medline
PY - 2025/8/22/pubmed
PY - 2025/8/22/entrez
KW - anovulation
KW - hyperandrogenism
KW - hyperinsulinemia
KW - hypothalamus
KW - metformin
KW - myo-inositol
KW - obesity
KW - oral contraceptive pills
KW - pcos
KW - sodium-glucose cotransporter-2 (sglt-2) inhibitors
SP - e88216
EP - e88216
JF - Cureus
JO - Cureus
VL - 17
IS - 7
N2 - Polycystic ovary syndrome (PCOS) is the most common endocrine disorder that significantly affects both obese and non-obese women of reproductive age. Besides genetic and epigenetic factors, obesity and insulin resistance (IR) play a key role in the pathogenesis of PCOS, contributing to its endocrine, reproductive, and metabolic manifestations. Even though metformin remains a well-established treatment in the management of PCOS, emerging therapies and integrative approaches warrant comparison. This narrative review aims to understand the pathophysiology of PCOS and compare the role of metformin with that of new emerging therapies, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors, oral contraceptive pills (OCPs), inositol supplements, and lifestyle modifications, thereby empowering clinicians to provide personalized medicine based on each patient's unique presentation. This review explores the safety, efficacy, and clinical outcomes of these interventions on weight reduction, hormonal balance, menstrual regularity, and metabolic outcomes in both obese and non-obese women with PCOS.
SN - 2168-8184
UR - https://www.unboundmedicine.com/prime/citation/40842765/Revisiting_Metformin_in_the_Management_of_Polycystic_Ovary_Syndrome_(PCOS).
DB - PRIME
DP - Unbound Medicine
ER -
